Biomarin has granted Ascendis a non-exclusive, worldwide license to use navepegritide, the active ingredient in the latter ...

The U.S. is scrambling to compete with a strategically positioned China on the biotech stage as the Asian country surpasses ...

Well-known for its oncology efforts and making recent headlines for a rumored mega merger with AstraZeneca, Bristol Myers ...

With the approval, Eli Lilly’s Mounjaro becomes the first dual GIP/GLP-1 receptor agonist indicated to lower the risk of ...

Teva Pharmaceuticals is the 'stalking horse bidder' to kick off the auction process for BioXcel Therapeutics' AI-derived ...

Current leaders Eli Lilly and Novo Nordisk have cornered the early market for weight loss therapeutics, but several other ...

Shares of Germany-based BioNTech were down as much as 8% Friday after announcing a Phase 2 trial of autogene cevumeran would ...

The FDA has placed a clinical hold on RGX-121 after small nodules or cystic masses were detected in the spines of five ...

Setbacks to efforts to use Cellares’ automated platform to make an approved CAR-T cell therapy led BMS to terminate its ...

Lisraya carries a boxed warning typical of JAK inhibitors, but otherwise has a broad label that allows use in all adults with ...

The Phase 3 readout is the first for ivonescimab beyond non-small cell lung cancer to show a significant overall survival ...

The FDA granted the approval of Revolution Medicines' daraxonrasib, now to be known as Rasonque, in pancreatic adenocarcinoma ...